Ya-Qing Han

Ya-Qing Han

Auto-generated profile, based on publicly available information

Ya-Qing Han

Department of Thoracic Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2025 in Recent Patents on Anti-Cancer Drug Discovery
Verified
Journal Article
Closed access
PDF file
BZBosheng Zheng
Bosheng Zheng
WZWei Zhang
Wei Zhang
SXShaonan Xie
Shaonan Xie
YHYaqing Han
Yaqing Han
GLGuangjie Liu
Guangjie Liu
QLQingyi Liu
Qingyi Liu
Selinexor treats lung cancer, particularly non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). This review summarizes the prevalence and types of lung cancer and emphasizes the challenges associated with current treatments like resistance and limited effectiveness. Selinexor is a selective inhibitor of nuclear export (SINE) that has emerged as a potential therapy that targets the nuclear export of tumor suppressor proteins. The mechanisms of selinexor, its potential in combination therapies, and challenges like side effects and drug resistance are explained in this review. Key findings highlight the effectiveness of selinexor in preclinical studies, particularly against KRAS-mutant NSCLC and in combination with chemotherapy for SCLC. The review concludes with a discussion of future directions and underscores the potential of selinexor to improve the treatment strategies for lung cancer.

7 January 2023 in Asian Journal of Surgery
Verified
Journal Article
Open access
YHYa-Qing Han
Ya-Qing Han
KHKai-Hong Han
Kai-Hong Han
GLGuang-Jie Liu
Guang-Jie Liu
QLQingyi Liu
Qingyi Liu